Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis

[1]  G. Filippatos,et al.  Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction , 2021, European heart journal.

[2]  S. Achenbach,et al.  Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure , 2021, Cardiovascular Diabetology.

[3]  Neha J. Pagidipati,et al.  In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. , 2021, Journal of the American College of Cardiology.

[4]  M. Khan,et al.  Trends in Hospitalizations for Heart Failure, Acute Myocardial Infarction, and Stroke in the United States from 2004-2018. , 2021, American heart journal.

[5]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[6]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[7]  L. Allen,et al.  Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. , 2021, Journal of cardiac failure.

[8]  M. Khan,et al.  Causes of hospitalization in the USA between 2005 and 2018 , 2021, European heart journal open.

[9]  G. Filippatos,et al.  Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. , 2021, Journal of the American College of Cardiology.

[10]  P. Ponikowski,et al.  Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial , 2021, European journal of heart failure.

[11]  P. Ponikowski,et al.  Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial , 2021, European heart journal.

[12]  M. Böhm,et al.  Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study , 2021, Cardiovascular Diabetology.

[13]  G. Fonarow,et al.  2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2021, Journal of the American College of Cardiology.

[14]  J. Mehta,et al.  Effects of Sodium-Glucose Cotransporter 1 and 2 Inhibitors on Cardiovascular and Kidney Outcomes in Type 2 Diabetes: A Meta-analysis Update. , 2020, American heart journal.

[15]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[16]  J. Mehta,et al.  Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials. , 2020, American heart journal.

[17]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[18]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[19]  S. Verma,et al.  Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors , 2020, JACC. Basic to translational science.

[20]  H. Heerspink,et al.  Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF) , 2020, European journal of heart failure.

[21]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[22]  Publisher's Note , 2018, Anaesthesia.

[23]  R. Riley,et al.  Detecting small‐study effects and funnel plot asymmetry in meta‐analysis of survival data: A comparison of new and existing tests , 2017, Research synthesis methods.

[24]  J. Spertus,et al.  Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire , 2015, Circulation. Cardiovascular quality and outcomes.

[25]  Andrea Benedetti,et al.  Systematic review of methods for individual patient data meta- analysis with binary outcomes , 2014, BMC Medical Research Methodology.

[26]  Laura G. Qualls,et al.  Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. , 2013, American heart journal.

[27]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[28]  J. Spertus,et al.  Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. , 2000, Journal of the American College of Cardiology.